1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Drugs In Development, 2022, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 2, 3, 19 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 3 molecules, respectively.
Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Aspergillosis - Overview
- Aspergillosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Aspergillosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Aspergillosis - Companies Involved in Therapeutics Development
- Aspergillosis - Drug Profiles
- Aspergillosis - Dormant Projects
- Aspergillosis - Discontinued Products
- Aspergillosis - Product Development Milestones
- Featured News & Press Releases
- Sep 08, 2022: TFF Pharmaceuticals announces presentation of patient data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation
- Jun 24, 2022: Basilea announces approval for additional formulation of antifungal Cresemba (isavuconazole) in China
- Jun 17, 2022: Cresemba sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer
- Jan 12, 2022: Basilea announces approval of antifungal Cresemba(isavuconazole) for invasive aspergillosis in China
- Jan 07, 2022: Strong Cresemba (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea
- Dec 08, 2021: Continued strong Cresemba (isavuconazole) sales by Pfizer trigger USD 10 million sales milestone payment to Basilea
- Nov 29, 2021: SCYNEXIS to host Ibrexafungerp hospital pipeline update Call and KOL webcast for investors on December 6
- Nov 11, 2021: CHMP recommended extensions of indication for Noxafil
- Nov 08, 2021: TFF Pharmaceuticals announces completion of dosing of phase 1b study for voriconazole inhalation powder in mild to moderate asthma patients
- Nov 08, 2021: TFF Pharmaceuticals announces completion of dosing of phase 1b study for voriconazole inhalation powder in mild to moderate asthma patients
- Sep 30, 2021: Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of isavuconazole in Japan
- Sep 27, 2021: Obtained additional approval for the indication of Noxafil, a treatment for deep-seated fungal diseases
- Sep 16, 2021: CHMP recommended extensions of Noxafil indication
- Sep 15, 2021: Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
- Jul 27, 2021: Cidara Therapeutics to present new data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Aspergillosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Aspergillosis - Dormant Projects, 2022
- Aspergillosis - Discontinued Products, 2022
- Number of Products under Development for Aspergillosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbGenics Life Sciences Pvt Ltd
- Argenx SE
- Basilea Pharmaceutica Ltd
- Bio-Synectics Inc
- Biosergen AS
- Cellix Bio Pvt Ltd
- Cidara Therapeutics Inc
- CSPC Pharmaceutical Group Ltd
- F2G Ltd
- FUJIFILM Toyama Chemical Co Ltd
- Galephar Pharmaceutical Research Inc
- Shaanxi Synthetic Pharmaceutical Co Ltd
- Immupharma Plc
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- Matinas BioPharma Holdings Inc
- Merck & Co Inc
- Molecular Express Inc
- Mycovia Pharmaceuticals Inc
- Nanomerics Ltd
- Novabiotics Ltd
- Pfizer Inc
- Pulmocide Ltd
- Pulmonomy Inc
- Regeneron Pharmaceuticals Inc
- Satellos Bioscience Inc
- Scynexis Inc
- Stadius Biopharma LLC
- TFF Pharmaceuticals Inc
- Trilogy Therapeutics Inc
- Visterra Inc
